Robert S.Terzoli, Jr.
Associate
Intellectual Property
rterzoli@seyfarth.com
More About Robert
Protecting intellectual property rights is integral for single innovators to multinational corporations. Robert assists these innovators in obtaining and protecting their rights for all intangible assets, including trademark, copyright, patents, and trade secrets. Robert has also assisted clients with product liability and commercial litigation issues, focusing on FDA and other regulated products.
Robert’s intellectual property practice involves both litigation and trademark portfolio management. Robert has assisted clients in the pharmaceutical, alcoholic beverage, and computer technology spaces on both intellectual property and product liability matters. Robert litigates infringement disputes relating to all facets of IP, and has experience with opposition and cancellation proceedings before the Trademark Trial and Appeal Board of the United States Patent and Trademark Office. Robert also has experience before federal trial and appellate courts. He has been a member of several trial teams where he has drafted numerous motions, prepared fact and expert witnesses, and assisted with taking witness testimony at trial in multi-million dollar lawsuits. He has also drafted on numerous motions, appellate briefing and has participated in several joint defense groups in complex litigation matters.
In addition to his IP and product liability litigation experience, Robert has stayed on top of the developing situations domestically and internationally. He has advised clients on FDA and regulatory matters. Robert publishes numerous updates on these developments.
Robert earned his JD from Georgetown University Law Center and a BA in History from UCLA. He attended law school part-time while working full-time as a law clerk at a leading intellectual property boutique law firm focused on issues facing the biotechnology, pharmaceutical, nanotechnology, and chemical industries. Previously, he was an Analyst at Arrowhead Research Corporation, a publicly-traded private equity firm focused on investments in the life sciences. While at Arrowhead, he reported to the General Counsel and assisted on M&A and contentious employment law matters. He also sourced and evaluated potential investment targets for management.
Robert’s intellectual property practice involves both litigation and trademark portfolio management. Robert has assisted clients in the pharmaceutical, alcoholic beverage, and computer technology spaces on both intellectual property and product liability matters. Robert litigates infringement disputes relating to all facets of IP, and has experience with opposition and cancellation proceedings before the Trademark Trial and Appeal Board of the United States Patent and Trademark Office. Robert also has experience before federal trial and appellate courts. He has been a member of several trial teams where he has drafted numerous motions, prepared fact and expert witnesses, and assisted with taking witness testimony at trial in multi-million dollar lawsuits. He has also drafted on numerous motions, appellate briefing and has participated in several joint defense groups in complex litigation matters.
In addition to his IP and product liability litigation experience, Robert has stayed on top of the developing situations domestically and internationally. He has advised clients on FDA and regulatory matters. Robert publishes numerous updates on these developments.
Robert earned his JD from Georgetown University Law Center and a BA in History from UCLA. He attended law school part-time while working full-time as a law clerk at a leading intellectual property boutique law firm focused on issues facing the biotechnology, pharmaceutical, nanotechnology, and chemical industries. Previously, he was an Analyst at Arrowhead Research Corporation, a publicly-traded private equity firm focused on investments in the life sciences. While at Arrowhead, he reported to the General Counsel and assisted on M&A and contentious employment law matters. He also sourced and evaluated potential investment targets for management.
- JD, Georgetown University Law Center
- BA, University of California, Los Angeles
Certifications
- Certified Health Care Institute (HCI) professional, Seyfarth Shaw LLP (2022)
- California
- District of Columbia
Related Key Industries
Related News & Insights
-
Blog Post
Jul 18, 2024
NLRB’s Non-Compete Power Grab – Can Employers Avoid NLRB’s Oversight?
-
Sponsored Events
Jun 24 - Jun 26, 2024
Seyfarth to Sponsor 2024 AHLA Annual Meeting
-
Blog Post
Jun 11, 2024
U.S. Isn’t Everything – The Importance for U.S. Entities to Obtain Trademark Protection Abroad (Yes, that includes Canada)
-
Attorney Publication
Oct 2, 2023
Now Available! 50-State Survey of Health Care Information Privacy Laws (2023-2024 Edition)
- Co-Contributor, "50-State Survey of Health Care Information Privacy Laws," Legal Update, Seyfarth Shaw LLP (October 2, 2023)
- Co-Author, "FDA Issues Emergency Use Authorization for COVID-19 Vaccine," Legal Update, Seyfarth Shaw LLP (December 14, 2020)
- Co-Author, "FDA Approves Veklury (remdesivir) As The First Treatment For COVID-19," Legal Update, Seyfarth Shaw LLP (October 26, 2020)
- Co-Author, "Chinese Manufacturers of Personal Protective Equipment Gave False U.S. Agent Information to Food and Drug Administration," Legal Update, Seyfarth Shaw LLP (June 24, 2020)
- Co-Author, "FDA Revokes Emergency Use Authorization For Highly Watched Chloroquine and Hydroxychloroquine - But They Can Still Be Prescribed," Legal Update, Seyfarth Shaw LLP (June 18, 2020)
- Co-Author, "FDA Revises Guidance on Face Masks, Respirators, and Face Shields to Address Covid-19 Concerns," Legal Update, Seyfarth Shaw LLP (May 29, 2020)
- Co-Author, "FDA Updates Emergency Use Authorization For Chinese Respirators," Legal Update, Seyfarth Shaw LLP (May 8, 2020)
- Co-Author, "Small and Micro Businesses Alert: USPTO Announces Program for Applications Covering Prevention and Treatment of COVID-19," Legal Update, Seyfarth Shaw LLP (May 8, 2020)
- Co-Author, "FDA Collection and Labeling Protocols For Use of Convalescent Plasma As A Treatment for COVID-19," Legal Update, Seyfarth Shaw LLP (April 28, 2020)
- Co-Author, "FDA Provides Safety Communication Relating to Use of Antimalarial Drugs Hydroxychloroquine and Chloroquine In the Treatment of COVID-19," Legal Update, Seyfarth Shaw LLP (April 28, 2020)
- Co-Author, "FDA Provides Guidance on How to Request Authorization to Use Convalescent Plasma as a Treatment for COVID-19," Legal Update, Seyfarth Shaw LLP (April 27, 2020)
- Co-Author, "FDA Authorizes Synthetic Nasal Swab to Increase COVID-19 Testing," Legal Update, Seyfarth Shaw LLP (April 22, 2020)
- Co-Author, "Guide For General Public: FDA Explains How Everyone Can “Make a Difference” During COVID-19 With Simple Infographic, Update," Legal Update, Seyfarth Shaw LLP (April 21, 2020)
- Co-Author, "FDA and NCI to Review COVID-19 Antibody Tests Marketed Under FDA Guidance Permitting Sale Without FDA Authorization," Legal Update, Seyfarth Shaw LLP (April 17, 2020)
- Co-Author, "Head to Toe: Summary of FDA COVID-19 Guidance Relating to Gowns, Other Apparel, and Gloves," Legal Update, Seyfarth Shaw LLP (April 13, 2020)
- Co-Author, "FDA Announces the Creation of CTAP—Coronavirus Treatment Acceleration Program—to Assist Drug Developers and Evaluators," Legal Update, Seyfarth Shaw LLP (April 10, 2020)
- Co-Author, "FDA Issues Updated Guidance Relating to its Enforcement Policy for Face Masks and Respirators," Legal Update, Seyfarth Shaw LLP (April 8, 2020)
- Co-Author, "CDC Provides Recommendations for Respirators When N95 Respirators Are Not Available in COVID-19 Crisis," Legal Update, Seyfarth Shaw LLP (April 7, 2020)
- Co-Author, "FDA Issues Guidance Documents Directed to Blood Donations as Part of COVID-19 Public Health Emergency Measures," Legal Update, Seyfarth Shaw LLP (April 3, 2020)
- Co-Author, "FDA Issues Guidance Regarding Alcohol-Based Hand Sanitizers For COVID-19 Prevention," Legal Update, Seyfarth Shaw LLP (April 3, 2020)
- Co-Author, "USPTO Extends Certain Patent-Related Timing Deadlines," Legal Update, Seyfarth Shaw LLP (April 3, 2020)
- Co-Author, "FDA Emergency Use Authorizations ('EUA') for COVID-19: What is an EUA and What is Currently Covered?," Legal Update, Seyfarth Shaw LLP (April 2, 2020)
- Co-Author, "FDA Eases Enforcement to Expand Remote Care of Pets and Food-Producing Animals," Legal Update, Seyfarth Shaw LLP (April 1, 2020)
- Co-Author, "FDA Eases Enforcement to Help Make More Ventilators Available," Legal Update, Seyfarth Shaw LLP (March 27, 2020)
- Co-Author, "False Advertising: Changing Your Business To Meet Market Needs During The COVID-19 Pandemic," Legal Update, Seyfarth Shaw LLP (March 25, 2020)
- Co-Author, "The USPTO Considers the Effects of the Coronavirus Outbreak to be an 'Extraordinary Situation:' What That Means for Trademark Applicants and Trademark Owners," Legal Update, Seyfarth Shaw LLP (March 21, 2020)
- Co-Author, "The USPTO Considers the Effects of the Coronavirus Outbreak to be an 'Extraordinary Situation:' What That Means for Patent Applicants and Patent Owners," Legal Update, Seyfarth Shaw LLP (March 20, 2020)
- Co-Author, "Tribal Immunity Cannot Be Asserted to Escape IPR Proceedings," BioLoquitur, Seyfarth Shaw LLP (July 25, 2018)
- Co-Author, "FDA Approves First Marijuana-Based Drug to Treat Epilepsy," BioLoquitur, Seyfarth Shaw LLP (July 5, 2018)
- Co-Author, "An Illustrated Guide to the USPTO’s New Memo on Method of Treatment Claims," BioLoquitur, Seyfarth Shaw LLP (June 29, 2018)
- Co-Author, "USPTO Announces Notice of Proposed Rulemaking for Claim Construction Standard used in PTAB Proceedings," BioLoquitur, Seyfarth Shaw LLP (May 8, 2018)
- Co-Author, "Part 2 of 2: Supreme Court and Inter Partes Review," BioLoquitur, Seyfarth Shaw LLP (April 30, 2018)
- Co-Author, "Part 1 of 2: Supreme Court and Inter Partes Review," BioLoquitur, Seyfarth Shaw LLP (April 30, 2018)
- Co-Author, "Federal Circuit Opens Door for PTAB Institution Decision Appeals," BioLoquitur, Seyfarth Shaw LLP (January 23, 2018)
- Co-Author, "No Longer the Stuff of Science Fiction: The FDA’s New Policy Approach to Regenerative Medicine Products," BioLoquitur, Seyfarth Shaw LLP (December 11, 2017)
- Co-Author, "Shire v. Amneal – Compound Claim Not Obvious and API Supplier Not Liable Under FDA Safe Harbor," BioLoquitur, Seyfarth Shaw LLP (October 6, 2015)
- Co-Author, "Patent Licensors Beware – No Challenge Clause Does Not Bar Challenge Before the PTAB," BioLoquitur, Seyfarth Shaw LLP (September 28, 2015)
More About Robert
Protecting intellectual property rights is integral for single innovators to multinational corporations. Robert assists these innovators in obtaining and protecting their rights for all intangible assets, including trademark, copyright, patents, and trade secrets. Robert has also assisted clients with product liability and commercial litigation issues, focusing on FDA and other regulated products.
Robert’s intellectual property practice involves both litigation and trademark portfolio management. Robert has assisted clients in the pharmaceutical, alcoholic beverage, and computer technology spaces on both intellectual property and product liability matters. Robert litigates infringement disputes relating to all facets of IP, and has experience with opposition and cancellation proceedings before the Trademark Trial and Appeal Board of the United States Patent and Trademark Office. Robert also has experience before federal trial and appellate courts. He has been a member of several trial teams where he has drafted numerous motions, prepared fact and expert witnesses, and assisted with taking witness testimony at trial in multi-million dollar lawsuits. He has also drafted on numerous motions, appellate briefing and has participated in several joint defense groups in complex litigation matters.
In addition to his IP and product liability litigation experience, Robert has stayed on top of the developing situations domestically and internationally. He has advised clients on FDA and regulatory matters. Robert publishes numerous updates on these developments.
Robert earned his JD from Georgetown University Law Center and a BA in History from UCLA. He attended law school part-time while working full-time as a law clerk at a leading intellectual property boutique law firm focused on issues facing the biotechnology, pharmaceutical, nanotechnology, and chemical industries. Previously, he was an Analyst at Arrowhead Research Corporation, a publicly-traded private equity firm focused on investments in the life sciences. While at Arrowhead, he reported to the General Counsel and assisted on M&A and contentious employment law matters. He also sourced and evaluated potential investment targets for management.
Robert’s intellectual property practice involves both litigation and trademark portfolio management. Robert has assisted clients in the pharmaceutical, alcoholic beverage, and computer technology spaces on both intellectual property and product liability matters. Robert litigates infringement disputes relating to all facets of IP, and has experience with opposition and cancellation proceedings before the Trademark Trial and Appeal Board of the United States Patent and Trademark Office. Robert also has experience before federal trial and appellate courts. He has been a member of several trial teams where he has drafted numerous motions, prepared fact and expert witnesses, and assisted with taking witness testimony at trial in multi-million dollar lawsuits. He has also drafted on numerous motions, appellate briefing and has participated in several joint defense groups in complex litigation matters.
In addition to his IP and product liability litigation experience, Robert has stayed on top of the developing situations domestically and internationally. He has advised clients on FDA and regulatory matters. Robert publishes numerous updates on these developments.
Robert earned his JD from Georgetown University Law Center and a BA in History from UCLA. He attended law school part-time while working full-time as a law clerk at a leading intellectual property boutique law firm focused on issues facing the biotechnology, pharmaceutical, nanotechnology, and chemical industries. Previously, he was an Analyst at Arrowhead Research Corporation, a publicly-traded private equity firm focused on investments in the life sciences. While at Arrowhead, he reported to the General Counsel and assisted on M&A and contentious employment law matters. He also sourced and evaluated potential investment targets for management.
- JD, Georgetown University Law Center
- BA, University of California, Los Angeles
Certifications
- Certified Health Care Institute (HCI) professional, Seyfarth Shaw LLP (2022)
- California
- District of Columbia
Related Key Industries
Related News & Insights
-
Blog Post
Jul 18, 2024
NLRB’s Non-Compete Power Grab – Can Employers Avoid NLRB’s Oversight?
-
Sponsored Events
Jun 24 - Jun 26, 2024
Seyfarth to Sponsor 2024 AHLA Annual Meeting
-
Blog Post
Jun 11, 2024
U.S. Isn’t Everything – The Importance for U.S. Entities to Obtain Trademark Protection Abroad (Yes, that includes Canada)
-
Attorney Publication
Oct 2, 2023
Now Available! 50-State Survey of Health Care Information Privacy Laws (2023-2024 Edition)
- Co-Contributor, "50-State Survey of Health Care Information Privacy Laws," Legal Update, Seyfarth Shaw LLP (October 2, 2023)
- Co-Author, "FDA Issues Emergency Use Authorization for COVID-19 Vaccine," Legal Update, Seyfarth Shaw LLP (December 14, 2020)
- Co-Author, "FDA Approves Veklury (remdesivir) As The First Treatment For COVID-19," Legal Update, Seyfarth Shaw LLP (October 26, 2020)
- Co-Author, "Chinese Manufacturers of Personal Protective Equipment Gave False U.S. Agent Information to Food and Drug Administration," Legal Update, Seyfarth Shaw LLP (June 24, 2020)
- Co-Author, "FDA Revokes Emergency Use Authorization For Highly Watched Chloroquine and Hydroxychloroquine - But They Can Still Be Prescribed," Legal Update, Seyfarth Shaw LLP (June 18, 2020)
- Co-Author, "FDA Revises Guidance on Face Masks, Respirators, and Face Shields to Address Covid-19 Concerns," Legal Update, Seyfarth Shaw LLP (May 29, 2020)
- Co-Author, "FDA Updates Emergency Use Authorization For Chinese Respirators," Legal Update, Seyfarth Shaw LLP (May 8, 2020)
- Co-Author, "Small and Micro Businesses Alert: USPTO Announces Program for Applications Covering Prevention and Treatment of COVID-19," Legal Update, Seyfarth Shaw LLP (May 8, 2020)
- Co-Author, "FDA Collection and Labeling Protocols For Use of Convalescent Plasma As A Treatment for COVID-19," Legal Update, Seyfarth Shaw LLP (April 28, 2020)
- Co-Author, "FDA Provides Safety Communication Relating to Use of Antimalarial Drugs Hydroxychloroquine and Chloroquine In the Treatment of COVID-19," Legal Update, Seyfarth Shaw LLP (April 28, 2020)
- Co-Author, "FDA Provides Guidance on How to Request Authorization to Use Convalescent Plasma as a Treatment for COVID-19," Legal Update, Seyfarth Shaw LLP (April 27, 2020)
- Co-Author, "FDA Authorizes Synthetic Nasal Swab to Increase COVID-19 Testing," Legal Update, Seyfarth Shaw LLP (April 22, 2020)
- Co-Author, "Guide For General Public: FDA Explains How Everyone Can “Make a Difference” During COVID-19 With Simple Infographic, Update," Legal Update, Seyfarth Shaw LLP (April 21, 2020)
- Co-Author, "FDA and NCI to Review COVID-19 Antibody Tests Marketed Under FDA Guidance Permitting Sale Without FDA Authorization," Legal Update, Seyfarth Shaw LLP (April 17, 2020)
- Co-Author, "Head to Toe: Summary of FDA COVID-19 Guidance Relating to Gowns, Other Apparel, and Gloves," Legal Update, Seyfarth Shaw LLP (April 13, 2020)
- Co-Author, "FDA Announces the Creation of CTAP—Coronavirus Treatment Acceleration Program—to Assist Drug Developers and Evaluators," Legal Update, Seyfarth Shaw LLP (April 10, 2020)
- Co-Author, "FDA Issues Updated Guidance Relating to its Enforcement Policy for Face Masks and Respirators," Legal Update, Seyfarth Shaw LLP (April 8, 2020)
- Co-Author, "CDC Provides Recommendations for Respirators When N95 Respirators Are Not Available in COVID-19 Crisis," Legal Update, Seyfarth Shaw LLP (April 7, 2020)
- Co-Author, "FDA Issues Guidance Documents Directed to Blood Donations as Part of COVID-19 Public Health Emergency Measures," Legal Update, Seyfarth Shaw LLP (April 3, 2020)
- Co-Author, "FDA Issues Guidance Regarding Alcohol-Based Hand Sanitizers For COVID-19 Prevention," Legal Update, Seyfarth Shaw LLP (April 3, 2020)
- Co-Author, "USPTO Extends Certain Patent-Related Timing Deadlines," Legal Update, Seyfarth Shaw LLP (April 3, 2020)
- Co-Author, "FDA Emergency Use Authorizations ('EUA') for COVID-19: What is an EUA and What is Currently Covered?," Legal Update, Seyfarth Shaw LLP (April 2, 2020)
- Co-Author, "FDA Eases Enforcement to Expand Remote Care of Pets and Food-Producing Animals," Legal Update, Seyfarth Shaw LLP (April 1, 2020)
- Co-Author, "FDA Eases Enforcement to Help Make More Ventilators Available," Legal Update, Seyfarth Shaw LLP (March 27, 2020)
- Co-Author, "False Advertising: Changing Your Business To Meet Market Needs During The COVID-19 Pandemic," Legal Update, Seyfarth Shaw LLP (March 25, 2020)
- Co-Author, "The USPTO Considers the Effects of the Coronavirus Outbreak to be an 'Extraordinary Situation:' What That Means for Trademark Applicants and Trademark Owners," Legal Update, Seyfarth Shaw LLP (March 21, 2020)
- Co-Author, "The USPTO Considers the Effects of the Coronavirus Outbreak to be an 'Extraordinary Situation:' What That Means for Patent Applicants and Patent Owners," Legal Update, Seyfarth Shaw LLP (March 20, 2020)
- Co-Author, "Tribal Immunity Cannot Be Asserted to Escape IPR Proceedings," BioLoquitur, Seyfarth Shaw LLP (July 25, 2018)
- Co-Author, "FDA Approves First Marijuana-Based Drug to Treat Epilepsy," BioLoquitur, Seyfarth Shaw LLP (July 5, 2018)
- Co-Author, "An Illustrated Guide to the USPTO’s New Memo on Method of Treatment Claims," BioLoquitur, Seyfarth Shaw LLP (June 29, 2018)
- Co-Author, "USPTO Announces Notice of Proposed Rulemaking for Claim Construction Standard used in PTAB Proceedings," BioLoquitur, Seyfarth Shaw LLP (May 8, 2018)
- Co-Author, "Part 2 of 2: Supreme Court and Inter Partes Review," BioLoquitur, Seyfarth Shaw LLP (April 30, 2018)
- Co-Author, "Part 1 of 2: Supreme Court and Inter Partes Review," BioLoquitur, Seyfarth Shaw LLP (April 30, 2018)
- Co-Author, "Federal Circuit Opens Door for PTAB Institution Decision Appeals," BioLoquitur, Seyfarth Shaw LLP (January 23, 2018)
- Co-Author, "No Longer the Stuff of Science Fiction: The FDA’s New Policy Approach to Regenerative Medicine Products," BioLoquitur, Seyfarth Shaw LLP (December 11, 2017)
- Co-Author, "Shire v. Amneal – Compound Claim Not Obvious and API Supplier Not Liable Under FDA Safe Harbor," BioLoquitur, Seyfarth Shaw LLP (October 6, 2015)
- Co-Author, "Patent Licensors Beware – No Challenge Clause Does Not Bar Challenge Before the PTAB," BioLoquitur, Seyfarth Shaw LLP (September 28, 2015)